Literature DB >> 27491937

Synthesis and Evaluation of A New Series of Thiazole Derivatives as Potential Antitumor Agents and MMP Inhibitors.

Zafer Asim Kaplancikli, Mehlika Dilek Altıntop1, Ozlem Atli, Belgin Sever, Merve Baysal, Halide Edip Temel, Fatih Demirci2, Ahmet Ozdemir1.   

Abstract

BACKGROUND: In recent years, the relationship between overexpression of matrix metalloproteinases (MMPs) and tumor invasion/metastasis has prompted researchers to develop MMP inhibitors as anticancer drugs.
OBJECTIVE: The aim of this study was to design and synthesize new thiazole-based anticancer agents targeting MMPs.
METHOD: New thiazole derivatives were synthesized and investigated for their cytotoxic effects on A549 human lung adenocarcinoma, MCF-7 human breast adenocarcinoma and NIH/3T3 mouse embryonic fibroblast cell lines using MTT assay. The potential inhibitory effects of the best candidates on gelatinases (MMP-2, MMP-9), and collagenases (MMP-1, MMP-8, MMP-13) were evaluated.
RESULTS: Ethyl 2-[2-((4-amino-5-(phenoxymethyl)-4H-1,2,4-triazol-3-yl)thio)acetamido]-4-methylthiazole-5-carboxylate (3) was found to be the most promising anticancer agent against MCF-7 cell line due to its selective inhibitory effect on MCF-7 cells with an IC50 value of 20.6±0.3 μg/mL when compared with cisplatin (IC50= 35.31±0.51 μg/mL). Compound 3 also showed multiple MMP (MMP-1, MMP-8 and MMP-9) inhibitory activity (10.56±1.70, 20 and 7.28±1.49%, respectively).
CONCLUSION: The notable anticancer activity and selectivity of compound 3 on MCF-7 cell line can be attributed to multiple MMP inhibition potential. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Thiazole; anticancer activity; matrix metalloproteinase; oxadiazole; triazole

Mesh:

Substances:

Year:  2017        PMID: 27491937     DOI: 10.2174/1871520616666160802113620

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  3 in total

1.  LncRNA RP3-326I13.1 promotes cisplatin resistance in lung adenocarcinoma by binding to HSP90B and upregulating MMP13.

Authors:  Huixin Zhou; Xiaolu Huang; Wenjing Shi; Shihao Xu; Jie Chen; Kate Huang; Yumin Wang
Journal:  Cell Cycle       Date:  2022-03-17       Impact factor: 5.173

2.  Microwave-Assisted Facile Synthesis, Anticancer Evaluation and Docking Study of N-((5-(Substituted methylene amino)-1,3,4-thiadiazol-2-yl)methyl) Benzamide Derivatives.

Authors:  Shailee V Tiwari; Sumaiya Siddiqui; Julio A Seijas; M Pilar Vazquez-Tato; Aniket P Sarkate; Deepak K Lokwani; Anna Pratima G Nikalje
Journal:  Molecules       Date:  2017-06-15       Impact factor: 4.411

3.  Synthesis and Evaluation of New Oxadiazole, Thiadiazole, and Triazole Derivatives as Potential Anticancer Agents Targeting MMP-9.

Authors:  Ahmet Özdemir; Belgin Sever; Mehlika Dilek Altıntop; Halide Edip Temel; Özlem Atlı; Merve Baysal; Fatih Demirci
Journal:  Molecules       Date:  2017-07-04       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.